APTO - Aptose Biosciences

-

$undefined

N/A

(N/A)

Aptose Biosciences NasdaqCM:APTO Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Location: 251 Consumers Road, Toronto, ON, M2J 4R3, Canada | Website: https://www.aptose.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.167M

Cash

7.962M

Avg Qtr Burn

-9.294M

Short % of Float

10.64%

Insider Ownership

24.80%

Institutional Own.

11.51%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tuspetinib / Venetoclax / Azacitidine triplet Details
Cancer, Leukemia, Acute myeloid leukemia

Phase 1/2

Data readout

Luxeptinib (CG-806) Details
Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Acute myeloid leukemia

Phase 1/2

Update

Tuspetinib mono/combo w/ Venetoclax Details
Cancer, Leukemia, Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia

Phase 1/2

Update

Tuspetinib (HM43239) & luxeptinib Details
Acute myeloid leukemia, B-cell malignancies, Relapsed/refractory acute myeloid leukemia

Failed

Discontinued

APTO-253 Details
Cancer, Acute myeloid leukemia, Myelodysplastic syndrome

Failed

Discontinued